Anteris Technologies Ltd's (ASX:AVR) Wayne Paterson tells Proactive's Andrew Scott the recent name change from Admedus is to reflect the single focus they have on structural heart and leveraging its assets into much more higher-value propositions. Paterson updates on its main trials which are underway and says he's extremely thrilled with the results to date from its first-in-human study. Paterson's expecting the company will end the year achieving all milestones set for 2020.
Anteris Technologies 'delivering on its goals despite pandemic'
Quick facts: Anteris Technologies Ltd
Price: 3.3 AUD
Market Cap: $19.5 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...FOR OUR FULL DISCLAIMER CLICK HERE